Page last updated: 2024-11-12

ludartin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ludartin: a TRPA1 channel activator; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID14355826
CHEMBL ID1097764
MeSH IDM000598671

Synonyms (4)

Synonym
ludartin
CHEMBL1097764 ,
bdbm50318394
6,8a-dimethyl-3-methylene-3a,4,5,7,7a,8a,8b,8c-octahydro-3h-1,8-dioxa-cyclopenta[h]cyclopropa[a]azulen-2-one (ludartin)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AromataseHomo sapiens (human)IC50 (µMol)0.05500.00001.290410.0000AID479369
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (15)

Processvia Protein(s)Taxonomy
negative regulation of chronic inflammatory responseAromataseHomo sapiens (human)
steroid biosynthetic processAromataseHomo sapiens (human)
estrogen biosynthetic processAromataseHomo sapiens (human)
androgen catabolic processAromataseHomo sapiens (human)
syncytium formationAromataseHomo sapiens (human)
negative regulation of macrophage chemotaxisAromataseHomo sapiens (human)
sterol metabolic processAromataseHomo sapiens (human)
female genitalia developmentAromataseHomo sapiens (human)
mammary gland developmentAromataseHomo sapiens (human)
uterus developmentAromataseHomo sapiens (human)
prostate gland growthAromataseHomo sapiens (human)
testosterone biosynthetic processAromataseHomo sapiens (human)
positive regulation of estradiol secretionAromataseHomo sapiens (human)
female gonad developmentAromataseHomo sapiens (human)
response to estradiolAromataseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
iron ion bindingAromataseHomo sapiens (human)
steroid hydroxylase activityAromataseHomo sapiens (human)
electron transfer activityAromataseHomo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenAromataseHomo sapiens (human)
oxygen bindingAromataseHomo sapiens (human)
heme bindingAromataseHomo sapiens (human)
aromatase activityAromataseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
endoplasmic reticulumAromataseHomo sapiens (human)
endoplasmic reticulum membraneAromataseHomo sapiens (human)
membraneAromataseHomo sapiens (human)
endoplasmic reticulumAromataseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (29)

Assay IDTitleYearJournalArticle
AID1546506Antiproliferative activity against human BHY cells assessed as reduction in cell viability after 48 hrs by MTT assay2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Artemisia: a promising plant for the treatment of cancer.
AID1066880Cytotoxicity against human MCF7 cells assessed as growth inhibition by colorimetric sulphorhodamine B assay2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
Click chemistry inspired facile synthesis and bioevaluation of novel triazolyl analogs of Ludartin.
AID1066886Cytotoxicity against human A549 cells assessed as growth inhibition by colorimetric sulphorhodamine B assay2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
Click chemistry inspired facile synthesis and bioevaluation of novel triazolyl analogs of Ludartin.
AID765944Cytotoxicity against human THP1 cells assessed as cell growth inhibition at 50 uM after 48 hrs by sulphorhodamine B assay2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
Synthesis and biological evaluation of amino analogs of Ludartin: potent and selective cytotoxic agents.
AID335952Antiulcerogenic activity in Wistar rat assessed as cytoprotection against ethanol-induced gastric lesions at 40 mg/kg administered 60 mins before ethanol challenge
AID765940Cytotoxicity against human HCT116 cells assessed as cell growth inhibition at 50 uM after 48 hrs by sulphorhodamine B assay2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
Synthesis and biological evaluation of amino analogs of Ludartin: potent and selective cytotoxic agents.
AID1546532Cytotoxicity against mouse B16F10 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Artemisia: a promising plant for the treatment of cancer.
AID765942Cytotoxicity against human PC3 cells assessed as cell growth inhibition at 50 uM after 48 hrs by sulphorhodamine B assay2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
Synthesis and biological evaluation of amino analogs of Ludartin: potent and selective cytotoxic agents.
AID1546533Cytotoxicity against human A431 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Artemisia: a promising plant for the treatment of cancer.
AID765943Cytotoxicity against human THP1 cells assessed as cell growth inhibition after 48 hrs by sulphorhodamine B assay2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
Synthesis and biological evaluation of amino analogs of Ludartin: potent and selective cytotoxic agents.
AID1546505Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Artemisia: a promising plant for the treatment of cancer.
AID1546507Antiproliferative activity against human MIAPaCa2 cells assessed as reduction in cell viability after 48 hrs by MTT assay2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Artemisia: a promising plant for the treatment of cancer.
AID479369Inhibition of human placental microsome CYP192010Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10
Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19).
AID1066881Cytotoxicity against human THP1 cells assessed as growth inhibition by colorimetric sulphorhodamine B assay2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
Click chemistry inspired facile synthesis and bioevaluation of novel triazolyl analogs of Ludartin.
AID1546508Antiproliferative activity against human COLO205 cells assessed as reduction in cell viability after 48 hrs by MTT assay2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Artemisia: a promising plant for the treatment of cancer.
AID765946Cytotoxicity against human A549 cells assessed as cell growth inhibition at 50 uM after 48 hrs by sulphorhodamine B assay2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
Synthesis and biological evaluation of amino analogs of Ludartin: potent and selective cytotoxic agents.
AID765939Cytotoxicity against human HCT116 cells assessed as cell growth inhibition after 48 hrs by sulphorhodamine B assay2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
Synthesis and biological evaluation of amino analogs of Ludartin: potent and selective cytotoxic agents.
AID1546509Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Artemisia: a promising plant for the treatment of cancer.
AID1066887Cytotoxicity against human PC3 cells assessed as growth inhibition at 50 uM by colorimetric sulphorhodamine B assay2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
Click chemistry inspired facile synthesis and bioevaluation of novel triazolyl analogs of Ludartin.
AID1066882Cytotoxicity against human MCF7 cells assessed as growth inhibition at 50 uM by colorimetric sulphorhodamine B assay2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
Click chemistry inspired facile synthesis and bioevaluation of novel triazolyl analogs of Ludartin.
AID765941Cytotoxicity against human PC3 cells assessed as cell growth inhibition after 48 hrs by sulphorhodamine B assay2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
Synthesis and biological evaluation of amino analogs of Ludartin: potent and selective cytotoxic agents.
AID174706Cytoprotective effect at an oral dose of 40 mg/kg1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
Structure-activity relationship in the gastric cytoprotective effect of several sesquiterpene lactones.
AID1066883Cytotoxicity against human HCT116 cells assessed as growth inhibition by colorimetric sulphorhodamine B assay2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
Click chemistry inspired facile synthesis and bioevaluation of novel triazolyl analogs of Ludartin.
AID1066888Cytotoxicity against human A549 cells assessed as growth inhibition at 50 uM by colorimetric sulphorhodamine B assay2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
Click chemistry inspired facile synthesis and bioevaluation of novel triazolyl analogs of Ludartin.
AID1066889Cytotoxicity against human T98G cells assessed as growth inhibition at 50 uM by colorimetric sulphorhodamine B assay2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
Click chemistry inspired facile synthesis and bioevaluation of novel triazolyl analogs of Ludartin.
AID765945Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by sulphorhodamine B assay2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
Synthesis and biological evaluation of amino analogs of Ludartin: potent and selective cytotoxic agents.
AID1066890Cytotoxicity against human T98G cells assessed as growth inhibition by colorimetric sulphorhodamine B assay2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
Click chemistry inspired facile synthesis and bioevaluation of novel triazolyl analogs of Ludartin.
AID1066885Cytotoxicity against human PC3 cells assessed as growth inhibition by colorimetric sulphorhodamine B assay2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
Click chemistry inspired facile synthesis and bioevaluation of novel triazolyl analogs of Ludartin.
AID1066884Cytotoxicity against human HCT116 cells assessed as growth inhibition at 50 uM by colorimetric sulphorhodamine B assay2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
Click chemistry inspired facile synthesis and bioevaluation of novel triazolyl analogs of Ludartin.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (14.29)18.2507
2000's0 (0.00)29.6817
2010's5 (71.43)24.3611
2020's1 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 13.01

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index13.01 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index5.21 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (13.01)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (12.50%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]